Merck Announces Combined Therapeutics as North American 2020 Advance Biotech Grant Program Winner
Nov 26 2020 Read 449 Times
Merck has announced that Combined Therapeutics Inc has been selected as the North American winner of its 2020 Advance Biotech Grant Program. The biotechnology company was selected for its innovative nucleic acid platform which, combined with virotherapy, has the potential to treat liver cancer by using a lipid nanoparticle delivery system.
“We help pioneering biotech companies bring lifesaving drugs to market, faster,” said Andrew Bulpin, Head of Process Solutions, Life Science, at Merck. “Combined Therapeutics’ platform shows promise to treat liver cancer, which affects thousands of people across the world each year.”
As part of the award, Combined Therapeutics Inc will receive in-kind Merck products and consultation in downstream processing, formulation excipients and sterile filtration.
Combined Therapeutics Inc is in pre-clinical development of a platform to treat cancer by targeting solid tumours, while protecting the healthy tissue of key organs. Virotherapy is a treatment that uses a modified virus to target and destroy cancer cells. However, this approach can often lead to low patient response and safety concerns due to poor targeting. Combined Therapeutics aims to direct and enhance virotherapies while preventing off-target effects. With its potential to target specific cells only, this combined approach shows promise to be a safe and effective therapy for cancer.
“Merck’s expertise in large biomolecule filtration, scale-up and extensive range of excipients will play a pivotal role in moving this project forward to GMP and clinical trials,” said Romain Micol, Chief Executive Officer, Combined Therapeutics Inc. “We are honoured to have been selected as the winner of Merck’s Advance Biotech Grant, and we look forward to the collaboration.”
Since 2014, Merck’s Advance Biotech Grant Program has awarded technologies and consultation to 28 biotechnology companies. These grants have been used to support biotech companies whose missions are to help patients suffering from cancer, brain tumours, osteoarthritis and cardiovascular disorders.
More information online
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Edition Articles - The Movement Towards More Comprehensive Testing of Mycotoxins in Cannabis - Addressing proper HACCP implementation - Micropatterning: The art of micro-controlling...
View all digital editions
Jan 20 2021 Tokyo, Japan & online
Jan 23 2021 Digital Event
Jan 26 2021 Virtual event
Feb 23 2021 Cologne, Germany
Feb 28 2021 Virtual event